Cargando…
Impact of selective platelet inhibition in reducing cardiovascular risk – role of vorapaxar
This article reviews the pharmacology, clinical efficacy, and safety of vorapaxar in reducing cardiovascular risk. Vorapaxar is a tricyclic himbacine-derived reversible inhibitor of platelet surface protease activator receptor-1, which prevents thrombin from activating platelets. Two Phase III clini...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913541/ https://www.ncbi.nlm.nih.gov/pubmed/27366081 http://dx.doi.org/10.2147/VHRM.S81342 |